Michael Gelband’s Carisma Therapeutics CARM Stock Holding History

Michael Gelband’s Portfolio CARM Stock Details CARM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,190	Closed	-$27K	–	1779
2022 Q4	$27K	Buy	+2,190	New	+$23K	﹤0.01%	1562
2021 Q4	–	Sell	-2,917	Closed	-$46K	–	2193
2021 Q3	$46K	Buy	+2,917	New	+$140K	﹤0.01%	1977
2021 Q2	–	Sell	-13,109	Closed	-$682K	–	2378
2021 Q1	$682K	Buy	13,109 +11,184	+581%	+$528K	0.01%	1149
2020 Q4	$52K	Buy	+1,925	New	+$48.8K	﹤0.01%	1871
2020 Q1	–	Sell	-7,003	Closed	-$146K	–	1121
2019 Q4	$146K	Buy	+7,003	New	+$161K	﹤0.01%	1390

Other funds holding CARM

TOTUOP

Trustees of The University of Pennsylvania Philaldelphia, Pennsylvania $104M AUM

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

DCM

Deuterium Capital Management Clearwater, Florida $92.4M AUM 35% 1-Year Est. Return

WIM

Wittenberg Investment Management Carlisle, Massachusetts $292M AUM 36.12% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Michael Gelband's CARM Position: Q1 2023 in Review

Michael Gelband sold out of Carisma Therapeutics (CARM) in Q1 2023, closing a stake of 2,190 shares — an estimated $27K sold.

Michael Gelband first reported a position in CARM in Q4 2019 and held it in 5 quarters. The position peaked at $682K in Q1 2021. 37 funds tracked by Wall St. Rank hold CARM as of Q1 2023.

Michael Gelband reported no remaining Carisma Therapeutics position as of Q1 2023 after selling out during the quarter.
Michael Gelband sold 2,190 Carisma Therapeutics shares in Q1 2023, an estimated $27K.
Michael Gelband first reported a position in Carisma Therapeutics in Q4 2019 and held it in 5 quarters.
Michael Gelband's Carisma Therapeutics position peaked at $682K in Q1 2021.
37 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q1 2023.

Based on ExodusPoint Capital Management's 13F filing for Q1 2023, filed 11 May 2023.